Dr Adel Aref
Senior HTA Analyst
School of Public Health
Faculty of Health and Medical Sciences
Dr. Aref is a Medical Oncologist (Master's degree in Clinical Oncology, Egypt, 2008, Specialty Certification of Medical Oncology, UK, 2013) with 10 years of clinical practice experience working across the University hospital sector in Egypt from 2005 till 2009, then in prestigious medical oncology centers across the gulf countries (Dubai & Bahrain) from 2009 till 2016. He has got training in clinical trials through number of workshops including the Cancer Clinical Trials Workshop (FLIMS – Switzerland 2015). He founded the MedicalSurvey-17 research group since 2012 and have succeeded in establishing number of projects and collaborations with other research bodies.
In 2016, Dr Aref moved to Australia to start PhD by research in medicine at the university of Adelaide which was accomplished in December 2019. His PhD project involved research in prostate cancer and the effect of metabolic factors on prostate cancer incidence and aggressiveness. He has been awarded a number of scholarships & grants including the competitive IPRS scholarship from University of Adelaide 2016, and the Royal Adelaide Hospital Clinical Research project grant for 2018. Dr Aref has gained good experience in working in multicultural environment (Dubai, Bahrain, Australia and Egypt), medical affairs and regularities, writing EOIs, Grants application, Ethics application, teaching, collaboration and data exchange plans, data preparation, exploration and analysis, in addition to presentation skills, and writing manuscripts and publications.
Currently, he is working as a senior analyst at AHTA - University of Adelaide. This role includes producing high-quality commentaries on pharmaceutical submissions lodged by the pharmaceutical industry, liaise with epidemiologist, health economists, pharmacologists, clinicians, develop and submit manuscripts to peer-reviewed journals, present research findings to relevant scientific conferences among other job activities and responsibilities.
Dr Aref PhD was about the effect of obesity and abnormal metabolic profile on prostate cancer incidence and aggressiveness. He has been working on two large data sets from Australia and the United States to explore the link and causal effect of obesity and abnormal lipid profile on prostate cancer. He was a member of the Lipid and Prostate cancer research group, based at SAHRMI , Adelaide, SA, working under the supervision of Prof. Lisa Butler, the team leader of the group.
-
Language Competencies
Language Competency Arabic Can read, write, speak, understand spoken and peer review English Can read, write, speak, understand spoken and peer review French Can read -
Education
Date Institution name Country Title 1997 - 2003 Ain Shams University Egypt MBBS Medicine -
Postgraduate Training
Date Title Institution Country 2016 - 2019 PhD The University of Adelaide Australia 2005 - 2008 Master Degree in Clinical Oncology Ain Shams Univeristy Egypt -
Certifications
Date Title Institution name Country 2013 Speciality Certification of Medical Oncology Royal College of Physican United Kingdom 2010 Medical Oncology Certification European Society of Medical Oncology Italy -
Research Interests
-
Journals
Year Citation 2021 Elghazaly, H., Aref, A. T., Anderson, B. O., Arun, B., Yip, C. H., Abdelaziz, H., . . . Elghazawy, H. (2021). The first BGICC consensus and recommendations for breast cancer awareness, early detection and risk reduction in low- and middle-income countries and the MENA region. International Journal of Cancer, 9 pages.
2019 El-Ghazaly, H., Bahie-Eldin, N., & Aref, A. (2019). Highlights from 11th Breast-Gynecological and Immunooncology International Cancer Conference (BGICC), 17–18 January 2019, Egypt. ecancermedicalscience, 13.
2018 Nassar, Z., Aref, A., Miladinovic, D., Mah, C., Raj, G., Hoy, A., & Butler, L. (2018). Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU International, 121(Suppl. 3), 9-21.
Scopus23 WoS23 Europe PMC112018 El-Ghazaly, H., Aref, A., & Bahie-eldin, N. (2018). Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt. ecancermedicalscience, 12.
2018 Aref, A., Vincent, A. D., O'Callaghan, M., Martin, S., Sutherland, P., Hoy, A., . . . Wittert, G. (2018). The inverse relationship between prostate specific antigen (PSA) and obesity. Endocrine-Related Cancer, 25(11), 933-941.
Scopus9 WoS8 Europe PMC52017 Fayed, R., Hamza, D., Abdallah, H., Kelany, M., Tahseen, A., & Aref, A. T. (2017). Do we need regional guidelines for breast cancer management in the MENA region? MENA breast cancer guidelines project. ecancermedicalscience, 11, 783.
Scopus3 Europe PMC22016 Aref, A., Hamza, D., & Fayed, R. (2016). Screening of Clinical Practice in Management of Progression on Trastuzumabi Metastatic Breast Cancer. Journal of cancer prevention and current research, 5(1), 4 pages. 2014 Dawoud, E., Aref, A. T., Shorbagy, D., & Hamza, D. (2014). Panitumumab plus FOLFIRI vs. Bevacizumab plus FOLFIRI for First Line Treatment of Metastatic Colorectal Cancer with Wild-Type KRAS Tumors; a retrospective study. Austral-Asian journal of cancer, 13(1). 2014 Dawoud, E., Aref, A. T., Shorbagy, D., & Hamza, D. (2014). Panitumumab plus FOLFIRI vs. Bevacizumab plus FOLFIRI for First Line Treatment of Metastatic Colorectal Cancer with Wild-Type KRAS Tumors; a retrospective study. Austral-Asian journal of cancer, 13(1). 2014 Farid, I., Hamza, I., El-Abd, D., Mohyi, A., AbdulLatif, M., Aref, A., & Hamza, D. (2014). Transforming growth factor-β1 gene expression in hepatocellular carcinoma: A preliminary report. Arab Journal of Gastroenterology, 15(3-4), 142-147.
Scopus2 WoS2 Europe PMC12013 Aref, A. T., & Hamza, D. (2013). Bevacizumab Beyond Progression in Metastatic NSCLC. Austral-Asian journal of cancer, 12. -
Conference Items
-
Working Paper
Year Citation 2014 Aref, A. T. (2014). New Options for Treatment of Metastatic Sarcoma Pose a Challenge in Selecting the Best One. ESMO Young Oncologist Journal Club. 2014 Aref, A. T. (2014). Ramucirumab and the Evolving Role of Targeted Therapy in Advanced Gastric Cancer. ESMO Young Oncologist Journal Club. 2013 Aref, A. T. (2013). Continuation of Bevacizumab with Second-Line Chemotherapy after the Standard First-Line Bevacizumab-Containing Therapy in mCRC: What is the value of KRAS status?. ESMO Young Oncologist Journal Club.
-
Memberships
Date Role Membership Country 2016 - ongoing Member ANZUP Australia 2012 - ongoing Co-Founder MedicalSurveys-17 Egypt 2009 - ongoing Member ESMO Swaziland 2009 - ongoing Board Member BGICC Egypt
Connect With Me
External Profiles
